About this trial
This randomized clinical trial evaluates two different endometrial preparation protocols-hormone replacement therapy (HRT) and natural cycle-for frozen embryo transfer (FET) in infertile women undergoing assisted reproductive technology (ART). The goal is to compare implantation, clinical pregnancy, and ongoing pregnancy outcomes.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
None
Disqualifiers
None
Trial design
Parallel
Treatments tested in this trial
hormone replacement therapy (HRT) group
DrugEstradiol valerate is initiated at 4 mg/day on day 2 of the menstrual cycle and is adjusted to 8 mg/day based on endometrial thickness. Once the endometrial thickness reaches ≥8 mm, progesterone supplementation is started (400 mg vaginal suppositories twice daily and 50 mg intramuscular injections daily) for 5 days before blastocyst transfer.
Treatment groups
Trial outcomes
Primary outcomes
Clinical pregnancy rate
presence of gestational sac on ultrasound at 6 weeks
Chemical pregnancy rate
Positive BHCG test greater than 25 mIU/ml after 12-16 days of embryo transfer
Secondary outcomes
Ongoing Pregnancy Rate
Pregnancy sustained beyond 20 weeks gestation
Early Miscarriage Rate
loss of a fetus before 12 weeks of gestation
Late Miscarriage Rate
loss of a fetus after 12 weeks and before 24 weeks
Live Birth Rate
Birth of at least one live neonate after 24 completed weeks of gestation
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Malihe Mahmoudinia
Lead sponsor
Mashhad University of Medical Sciences
Sponsor institution
This trial is not recruiting at the moment. You can still explore other options: